SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2021
(Exact Name of Registrant as Specified in its Charter)
|(State or Other Jurisdiction
of Incorporation or Organization)
|(Commission File Number)||(IRS Employer Identification|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code: (
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On September 24, 2021, Dr. Alison Fleming resigned from her positions as Executive Vice President and Chief Technical Officer of Collegium Pharmaceutical, Inc. (the “Company”), effective September 30, 2021. The Company appreciates Dr. Fleming’s many years of service and wishes her the best in her future endeavors.
Item 8.01 Other Information
Scott Sudduth, who joined the Company as Vice President, Supply Chain in 2018, has been promoted to succeed Dr. Fleming and will serve as the Company’s Executive Vice President, Technical Operations effective October 1, 2021.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: September 30, 2021||Collegium Pharmaceutical, Inc.|
|By:||/s/ Colleen Tupper|
|Name: Colleen Tupper|
|Title: Executive Vice President and Chief Financial Officer|